Cisatracurium besilate enhances the TRAIL-induced apoptosis of gastric cancer cells via p53 signaling

References

• Matsuzaki J, Tsugawa H, Suzuki H. Precision medicine approaches to prevent gastric cancer. Gut Liver. 2021 Jan 15;15(1):3–12.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Huang J, Chan PSF, et al. Global incidence and mortality of gastric cancer, 1980–2018. JAMA Network Open. 2021 Jul 1;4(7):e2118457.
   PubMed Web of Science ®Google Scholar
• Qu S. The effect of individualized operating room nursing in patients with gastric cancer undergoing operation during anesthesia convalescence. Chinese Remedies Clinics. 2020;20(19):3341–3342.
   Google Scholar
• Dai Y. Exploration and analysis of operating room nursing methods which can promote postoperative recovery of patients with gastric cancer surgery. Chinese Community Doctors. 2020;36(22):118–119.
   Google Scholar
• Movafegh A, Amini S, Sharifnia H, et al. Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia. Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):447–450.
   PubMed Web of Science ®Google Scholar
• VanderWeide LA, Abdel-Rasoul M, Gerlach AT. The Incidence of hypotension with continuous infusion atracurium compared to cisatracurium in the Intensive Care Unit. Int J Crit Illn Inj Sci. 2017 Apr-Jun;7(2):113–118.
   PubMedGoogle Scholar
• Wu Z, Wang S, Peng X, et al. Altered Cisatracurium pharmacokinetics and pharmacodynamics in patients with congenital heart defects. Drug Metab Dispos. 2016 Jan;44(1):75–82.
   PubMed Web of Science ®Google Scholar
• Lim J, Cox J, Nguyen T, et al. Cisatracurium dosing in a patient with hyperthermia. Am J Health-system Pharm. 2019 Jul 2;76(14):1029–1032.
   PubMed Web of Science ®Google Scholar
• Jiang A, Zhao H, Liu X, et al. Comparison of different muscle-relaxant anesthetics on growth, migration and invasion of gastric cancer cells. Anticancer Res. 2017 Aug;37(8):4371–4378.
   PubMed Web of Science ®Google Scholar
• Yabasin IB, Sanches JGP, Ibrahim MM, et al. Cisatracurium retards cell migration and invasion upon upregulation of p53 and inhibits the aggressiveness of colorectal cancer. Front Physiol. 2018;9:941.
   PubMed Web of Science ®Google Scholar
• Yabasin IB, Lu Z, Yu JC, et al. Cisatracurium-induced proliferation impairment and death of colorectal cancer cells, HCT116 is mediated by p53 dependent intrinsic apoptotic pathway in vitro. Biomed Pharmacother. 2017 Jul;91:320–329.
   PubMed Web of Science ®Google Scholar
• Lv W, Wang J, Zhang S. Effects of cisatracurium on epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma. Oncol Lett. 2019 Nov;18(5):5325–5331.
   PubMed Web of Science ®Google Scholar
• Russo A, Russo G. Ribosomal proteins control or bypass p53 during nucleolar stress. Int J Mol Sci. 2017;18(1):140.
   PubMed Web of Science ®Google Scholar
• Wu H, Zou Q, He H, et al. Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med. 2019 May;8(5):2484–2495.
   PubMed Web of Science ®Google Scholar
• Bui HTT, Le NH, Le QA, et al. Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL. Int J Med Sci. 2019;16(11):1412–1423.
   PubMed Web of Science ®Google Scholar
• Lin CP, Lin CS, Lin HH, et al. Bergapten induces G1 arrest and pro-apoptotic cascade in colorectal cancer cells associating with p53/p21/PTEN axis. Environ Toxicol. 2019 Mar;34(3):303–311.
   PubMed Web of Science ®Google Scholar
• He S, Ma X, Ye Y, et al. HEATR1 modulates cell survival in non-small cell lung cancer via activation of the p53/PUMA signaling pathway. Onco Targets Ther. 2019;12:4001–4011.
   PubMed Web of Science ®Google Scholar
• Sun Z, Qiu Z, Ma B, et al. Encorafenib enhances TRAIL-induced apoptosis of colorectal cancer cells dependent on p53/PUMA signaling. Cytotechnology. 2021 Feb;73(1):63–70.
   PubMed Web of Science ®Google Scholar
• Yu L, Liu Z, Qiu L, et al. Ipatasertib sensitizes colon cancer cells to TRAIL-induced apoptosis through ROS-mediated caspase activation. Biochem Biophys Res Commun. 2019 Nov 19;519(4):812–818.
   PubMed Web of Science ®Google Scholar
• Yuan X, Gajan A, Chu Q, et al. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018 Dec;37(4):733–748.
   PubMed Web of Science ®Google Scholar
• Deng D, Shah K. TRAIL of hope meeting resistance in cancer. Trends Cancer. 2020 Dec;6(12):989–1001.
   PubMed Web of Science ®Google Scholar
• Wong SHM, Kong WY, Fang CM, et al. The TRAIL to cancer therapy: hindrances and potential solutions. Crit Rev Oncol Hematol. 2019 Nov;143:81–94.
   PubMed Web of Science ®Google Scholar
• Baskar R, Fienberg HG, Khair Z, et al. TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis. Life Sci Alliance. 2019;2(6):e201900554.
   PubMed Web of Science ®Google Scholar
• Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87.
   PubMed Web of Science ®Google Scholar
• Yang X, Ma W. Cisatracurium inhibits the proliferation, migration and invasion of breast cancer cells by regulating the expression of miR-3174. Cell Mol Biol (Noisy-le-grand). 2020 Sep 30;66(6):1–7.
   PubMed Web of Science ®Google Scholar
• Lee YK, Chung Y, Lee JH, et al. The intricate role of p53 in adipocyte differentiation and function. Cells. 2020;9(12):2621.
   PubMed Web of Science ®Google Scholar
• Fu X, Wu S, Li B, et al. Functions of p53 in pluripotent stem cells. Protein Cell. 2020 Jan;11(1):71–78.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017 Sep;83:258–265.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Riscal R, Arena G, et al. Metabolic functions of the tumor suppressor p53: implications in normal physiology, metabolic disorders, and cancer. Mol Metab. 2020 Mar;33:2–22.
   PubMed Web of Science ®Google Scholar
• Galanos P, Vougas K, Walter D, et al. Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nat Cell Biol. 2016 Jul;18(7):777–789.
   PubMed Web of Science ®Google Scholar
• Nie K, Zheng Z, Wen Y, et al. Construction and validation of a TP53-associated immune prognostic model for gastric cancer. Genomics. 2020 Nov;112(6):4788–4795.
   PubMed Web of Science ®Google Scholar
• Li N, Xie C, Lu NH. p53, a potential predictor of Helicobacter pylori infection-associated gastric carcinogenesis? Oncotarget. 2016 Oct 4;7(40):66276–66286.
   PubMedGoogle Scholar